Rush also held positions of increasing responsibility at Siebel Systems, Quintiles Transnational Holdings, PricewaterhouseCoopers and Ernst & Young. Rush was Senior Vice President and CFO of Tekelec, a leading high-tech solutions and service provider that was acquired by Oracle. Rush oversaw the Company’s global financial operations, including Finance, Accounting, Tax, Treasury, Budgeting, M&A and Financial Planning, as well as all Information Technology functions. (formerly known as INC Research Holdings, Inc.) from August 2013 to February 2018. Rush served as Executive Vice President and Chief Financial Officer of Syneos Health, Inc. Greg Rush is Chief Financial Officer at Parexel and brings to the Company more than 30 years of experience leading global financial operations within the CRO and service industries. Peyton serves on the Board of Directors of Tandem Diabetes Care, Inc., as well as the Cancer Equity Initiative for Family Reach, a national 501(c)(3) organization dedicated to eradicating the financial barriers that accompany a cancer diagnosis. She currently represents Parexel on the Board of Directors for the Association of Clinical Research Organizations (ACRO). In 2020 she was named a Luminary by the Healthcare Businesswomen’s Association (HBA). Peyton holds a Masters’ in Healthcare Administration (MHA) from The Ohio State University and a Bachelor of Arts in Speech Communication from The University of Illinois at Urbana-Champaign. Peyton also was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen. Peyton also previously served as President, Consulting Services for the company, managing a portfolio of industry-leading pharma services (including acquisitions) focused on market access, reimbursement, patient programs, specialty pharmacy, specialty logistics and product commercialization. In this role, she led the creation of a new sourcing entity in Bern, Switzerland to support global manufacturer relations and a joint venture with Walgreens. She also was President, Global Sourcing and Manufacturer Relations, responsible for leadership of $150B in manufacturer sourcing relationships. Peyton has more than 25 years of leadership experience in the healthcare industry and prior to joining Parexel held several leadership positions with AmerisourceBergen, a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit.
In 2020, she led the company’s Biotech and Enterprise Commercial teams to record new business growth. Peyton Howell joined Parexel in May 2018 and leads the company’s Commercial and Consulting businesses along with its Corporate Business Development, Corporate Strategy, Marketing and Corporate Communications functions. Peyton Howell President, Consulting and Chief Commercial & Strategy Officer in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA). Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015. Prior to this, he held various senior operational and finance roles at Quintiles. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Macdonald served as CEO of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014.
He has nearly 25 years of experience in leading global biopharmaceutical services companies. Jamie Macdonald is Chief Executive Officer of Parexel.
0 kommentar(er)
